REG - ValiRx PLC - Proposed Appointment of Non-Executive Director

ValiRxAnnouncement

29/02/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc0175Fa&default-theme=true

RNS Number : 0175F  ValiRx PLC  29 February 2024

29 February 2024

 

ValiRx PLC ("ValiRx" or the "Company")

 

Proposed Appointment of Non-Executive Director

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to announce
that, subject to normal regulatory due diligence, it intends to appoint Martin
Gouldstone as a Non-Executive Director of the Company.

Martin is currently CEO of Oncimmune Holdings plc and has 30 years of
corporate finance and business development experience in contract research
organisations, healthcare and pharmaceutical sectors. Previously, Martin was a
Global Senior Vice President of Business Development at Owkin, Inc., where he
managed the commercial teams in the USA and Europe and led new strategic
research partnerships. More recently, Martin was Chief Business Officer at
Sensyne Health; Global Senior Vice President and Head of Capital Solutions for
Syneos Health; Chief Business Officer at BenevolentAI.

 

Martin was previously a Partner at Results Healthcare (now CG Results
Healthcare), where he co-led the healthcare practice; Head of Lifesciences in
the UK for BDO, M&A Lead for Europe at Quintiles (now IQVIA Inc), and held
business development and licensing lead roles at Confirmant Ltd and Sareum
Holdings PLC. Martin has extensive experience buying and selling deals across
Europe and the US, and in negotiating multi-year research partnerships.

 

Currently, Martin is also a Non-Executive Director of hVIVO plc (formerly Open
Orphan plc) and sits on the Board of Trustees of Orthopaedic Research UK.
Martin holds a BSc in Genetics and has completed a range of postgraduate
management courses.

 

Dr Kevin Cox, Chair of ValiRx PLC, commented "Martin will be an invaluable
addition to the Board of ValiRx and his extensive experience in our sector
will provide help and advice across all areas of the business. I am delighted
that he shares our vision for ValiRx and look forward to working with him."

 

Dr Suzy Dilly, CEO of ValiRx PLC commented "I'm delighted to be working with
Martin, drawing on his breadth of commercial experience in business growth and
deal making, bringing support to both our licencing activities and helping in
the growth of Inaphaea Biolabs."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 2476 796496

                                                   www.valirx.com (http://www.valirx.com/)

 Dr Suzanne Dilly, CEO                             Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz/)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

 

 

Notes for Editors

 

About ValiRx

UValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

 

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

 

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

 

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

 

For further information, visit: www.valirx.com

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABXGDDBSDDGSC